RE:ONCY Corporate Investor PresentationPatients in the Phase 2 Goblet-1 PDAC cohort, presented at ESMO 2023, are undergoing first-line treatment with a combination of pelareorep, atezolizumab, gemcitabine and nab-paclitaxel. The 13 evaluable patients enrolled in the first stage of the study have been evaluated based on a September 18, 2023 data cut-off date. The enrolled patient population included 93% of patients with metastatic disease (69% with liver metastases) and baseline ECOG scores of 0 (31%) and 1 (69%), with an average age of 61.2 years.
https://oncolyticsbiotech.com/wp-content/uploads/2024/01/Oncolytics.Deck_.January.pdf
March 07, 2024 - ONCY Q4 2023 & full year financial results
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlights/
"New translational data in breast and pancreatic cancer reported in the fourth quarter continued to highlight pelareorep’s role in stimulating tumor-directed immune responses and shaping the tumor microenvironment, affirming its immunotherapeutic mechanism of action (MOA)."